• How Dual-Action Inhibitors Tune p38α Dephosphorylation

  2026-09-15

  The reference preprint shows that selected p38α kinase inhibitors can both suppress kinase activity and accelerate WIP1-mediated removal of the activation-loop phospho-threonine. Its biochemical and X-ray structural evidence links this dual action to an inhibitor-stabilized activation-loop conformation that exposes the phosphatase-sensitive site, suggesting a route to more durable and selective kinase control.

• 5-Azacytidine: From DNMT Inhibition to Translation

  2026-09-15

  5-Azacytidine is best understood not only as a DNA demethylation agent, but also as a mechanistic probe linking DNMT trapping, DNA damage, ATR signaling, apoptosis, and combination sensitivity. This translational guide shows how to convert those activities into stronger leukemia and multiple myeloma research strategies.

• RITA: Separating Growth Arrest from Cell Death

  2026-09-14

  RITA (NSC 652287) is a p53-pathway research compound with pronounced activity in renal carcinoma models. This article explains how to interpret its effects by separating proliferation arrest, cell death, DNA damage, and tumor regression rather than relying on a single viability endpoint.

• ZK53 Activates ClpP to Arrest Lung Cancer

  2026-09-14

  This Nature Communications study identifies ZK53 as a selective activator of human mitochondrial ClpP and shows that uncontrolled mitochondrial proteolysis suppresses oxidative phosphorylation, activates ATM-mediated DNA damage signaling, and arrests lung squamous cell carcinoma growth. Its structure-guided and in vivo evidence establishes a mechanistic bridge between mitochondrial proteostasis and cell-cycle control, while also defining experiments needed to test whether ATM signaling is required for the response.

• Alcian Blue & Nuclear Fast Red Staining Kit Guide

  2026-09-13

  Build a clearer dual-color workflow for acid mucins, mucopolysaccharides, and chondrogenic differentiation. This practical guide connects tissue-section staining with mesenchymal stem cell assays while separating validated evidence from optimization starting points.

• Fluorinated-Sorbitol Polyplexes Improve mRNA Delivery

  2026-09-12

  The reference study develops fluorinated polyethyleneimine functionalized with sorbitol as a dual-mechanism carrier that promotes cellular uptake and endosomal escape. The formulation enabled reporter expression in macrophage-like cells and mice and produced SARS-CoV-2 spike vaccine responses comparable to a Moderna LNP comparator, supporting further evaluation of polymeric mRNA delivery.

• 5-Azacytidine Beyond Oncology: An Epigenetic Strategy

  2026-09-11

  A translational perspective on how 5-Azacytidine can connect DNMT inhibition, DNA demethylation, cell-state control, and emerging UHRF1–5-mC biology while defining the evidence, experimental safeguards, and limits of extending oncology findings into senile osteoporosis research.

• HyperScribe™ Poly (A) Tailing Kit Workflow

  2026-09-11

  Convert compatible in vitro-transcribed RNA into material better suited to stability-sensitive expression studies, transfection experiments, and micro-injection. This workflow combines controlled enzymatic polyadenylation with assay-specific quality checks, including a practical route for testing TCAIM–OGDH metabolic regulation.

• 7-AAD Cell Viability Assay Kit for CD38 CAR-T

  2026-09-10

  Apply membrane-integrity measurements to distinguish CD38 CAR-T cytotoxicity from fratricide and late cell death. This practical workflow combines 7-AAD with Annexin V, Calcein AM, and immunophenotyping to turn structural binder design into interpretable cellular evidence.

• Dual HER2–VEGFR-2 Targeting in Breast Cancer

  2026-09-10

  A 2026 study evaluated Lapatinib and Telatinib in HER2-negative MDA-MB-231 triple-negative breast cancer cells, linking dual tyrosine kinase inhibition with reduced proliferation, invadopodia formation, and two-dimensional tube formation. The findings support phenotype-first targeted cancer therapy research while leaving direct receptor engagement and combination synergy unresolved.

• Tubastatin A: HDAC6 Inhibitor Workflow

  2026-09-09

  Tubastatin A enables selective HDAC6 inhibition while linking α-tubulin acetylation to cell stress, inflammatory signaling, and regulated cell death. This practical workflow translates porcine cardiac-arrest findings into reproducible cell assays, biomarker panels, and troubleshooting decisions for cancer biology and translational research.

• Lypressin acetate: Practical Assay Workflows

  2026-09-09

  Lypressin acetate offers a versatile peptide-hormone tool for receptor signaling, antidiuretic biology, vasoconstriction research, and exploratory antiviral studies. This workflow-focused guide explains how to handle the peptide, build concentration–response assays, interpret activity data, and troubleshoot reproducibility problems.

• RITA (NSC 652287): From p53 Signal to Translation

  2026-09-08

  A translational framework for using RITA to connect MDM2–p53 biology, DNA cross-link stress, interpretable viability metrics, and tumor xenograft evidence.

• Cell Senescence β-Galactosidase Staining Kit Workflow

  2026-09-08

  Build a practical SA-β-Gal workflow for cultured cells and frozen sections, from plate setup through quantitative microscopy. The assay is especially useful for connecting pathway-directed treatments, such as HPV-16 E6 inhibition, with a visible senescence phenotype while preserving orthogonal validation.

• ISRIB (trans-isomer): ATF4 Beyond ER Stress

  2026-09-07

  ISRIB (trans-isomer) is a potent PERK inhibitor and integrated stress response modulator for dissecting ATF4-dependent biology. This article explains how its eIF2B-centered mechanism can be applied to liver fibrosis, ER stress research, apoptosis assays, and carefully controlled translational models.

7921 records 1/529 page Next 12345 下5页 Last page